Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cassava Sciences (SAVA)
NASDAQ:SAVA
Holding SAVA?
Track your performance easily
SAVA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$8.79 - $42.20
Previous Close$28.34
Volume2.88M
Average Volume (3M)3.43M
Market Cap
$1.36B
Enterprise Value$1.15B
Total Cash (Recent Filing)$207.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Nov 05, 2024EPS Estimate
-$0.73Last Dividend Ex-Date
Dec 13, 2012Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding47,976,166
10 Day Avg. Volume1,290,186
30 Day Avg. Volume3,427,762
Standard Deviation0.62
R-Squared0.00272
Alpha0.17
Financial Highlights & Ratios
Price to Book (P/B)7.19
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-18.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda59.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering2
Cassava Sciences News
PremiumCompany Announcements
Cassava Sciences Announces New CEO and Governance Changes
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe Phase 3 studies have Special Protocol Assessment (SPA) with the FDA and are supported by positive Phase 2b results.
Financial StrategyCassava is ramping up their active pharmaceutical ingredient purchases, securing increased outsource manufacturing capacity and exploring distribution capabilities.
Market OpportunitySimufilam targets a market opportunity that could result in annual sales approaching $10B.
Bears Say
ControversyA federal grand jury indictment of the former consultant of Cassava Sciences could pose significant long-term challenges.
InvestigationsDOJ and SEC investigations into the Company and two senior employees.
Legal IssuesA $40M loss contingency was recorded due to the ongoing SEC investigation.
---
Ownership Overview
34.10% Insiders
7.94% Mutual Funds
15.92% Other Institutional Investors
42.04% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SAVA FAQ
What was Cassava Sciences’s price range in the past 12 months?
Cassava Sciences lowest stock price was $8.79 and its highest was $42.20 in the past 12 months.
What is Cassava Sciences’s market cap?
Currently, no data Available
When is Cassava Sciences’s upcoming earnings report date?
Cassava Sciences’s upcoming earnings report date is Nov 05, 2024 which is in 47 days.
How were Cassava Sciences’s earnings last quarter?
Cassava Sciences released its earnings results on Aug 08, 2024. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of -$0.407 by $0.537.
Is Cassava Sciences overvalued?
According to Wall Street analysts Cassava Sciences’s price is currently Overvalued.
Does Cassava Sciences pay dividends?
Cassava Sciences pays a Notavailable dividend of $5.25 which represents an annual dividend yield of N/A. See more information on Cassava Sciences dividends here
What is Cassava Sciences’s EPS estimate?
Cassava Sciences’s EPS estimate is -$0.73.
How many shares outstanding does Cassava Sciences have?
Cassava Sciences has 47,976,166 shares outstanding.
What happened to Cassava Sciences’s price movement after its last earnings report?
Cassava Sciences reported an EPS of $0.13 in its last earnings report, beating expectations of -$0.407. Following the earnings report the stock price went down -13.841%.
Which hedge fund is a major shareholder of Cassava Sciences?
Among the largest hedge funds holding Cassava Sciences’s share is Gallacher Capital Management LLC. It holds Cassava Sciences’s shares valued at 7M.
---
Cassava Sciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
SAVA Sentiment 79%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 4.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.00%
12-Months-Change
Fundamentals
Return on Equity
-8.35%
Trailing 12-Months
Asset Growth
23.48%
Trailing 12-Months
Company Description
Cassava Sciences
Cassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
---
SAVA Earnings Call
Q2 2024
0:00 / 0:00
---
SAVA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering SAVA
1 Year
1 Year Success Rate
2/2 ratings generated profit
1 Year Average Return
+26.95%
reiterated a buy rating 3 months ago
Copying Elemer Piros's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +26.95% per trade.
---